XML 43 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stockholders' Equity (Tables)
9 Months Ended
Mar. 31, 2024
Stockholders' Equity  
Schedule of stock-based compensation expense in the consolidated statements of operations

We recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):

Three Months Ended March 31, 

    

Nine Months Ended March 31, 

    

2023

    

2024

2023

    

2024

Cost of goods sold

$

229

$

214

$

686

$

701

Selling, general and administrative

6,757

6,650

 

20,467

 

20,326

Research and development

126

205

 

375

 

459

Stock-based compensation expense

$

7,112

$

7,069

$

21,528

$

21,486

Schedule of stock option activity

Weighted

Average

Weighted-Average

Aggregate

Number of

Exercise

Remaining Contractual

Intrinsic Value

    

Options

    

Price

    

Term

    

(in thousands)

Outstanding at June 30, 2023

 

83,677

 

$

87.09

 

Granted

 

22,438

119.45

Exercised

 

(16,767)

82.90

Expired or forfeited

 

(4,375)

86.09

Outstanding at March 31, 2024

 

84,973

$

96.51

7.5 years

$

3,935

Exercisable at March 31, 2024

40,578

 

5.8 years

$

2,264

Summary of RSU award activity

Weighted-

Average

    

Shares

    

Fair Value

Nonvested at June 30, 2023

 

455,515

$

85.15

Granted

 

333,001

95.41

Vested

 

(389,042)

79.75

Forfeited

 

(5,253)

84.59

Nonvested at March 31, 2024

 

394,221

$

99.16